公开(公告)号：US20240352067A1

公开(公告)日：2024-10-24

申请号：US18648015

申请日：2024-04-26

Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Kwangho LEE ,  Sang Dal RHEE ,  Gildon CHOI ,  Imran ALI ,  Chong Hak CHAE ,  Moon Kook JEON ,  Seok Hee PARK ,  Youn Sook LEE

IPC: C07K5/117 ,  A61K38/00 ,  A61K47/54 ,  A61P1/00 ,  C07D207/04 ,  C07D403/06 ,  C07K5/097 ,  C07K5/103 ,  C07K5/107

CPC classification number: C07K5/1024 ,  A61K47/542 ,  A61P1/00 ,  C07D207/04 ,  C07D403/06 ,  C07K5/0823 ,  C07K5/1008 ,  C07K5/1016 ,  A61K38/00

Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

公开(公告)号：US20190284143A1

公开(公告)日：2019-09-19

申请号：US16347480

申请日：2017-11-01

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Kwangho LEE ,  Gildon CHOI ,  Na Ri LEE ,  Sang Jun PARK ,  Myoung Eun JUNG ,  Seong Jin KIM ,  Kyung-Min YANG ,  Jihee LEE

IPC: C07D239/48 ,  C07D405/12 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00

Abstract: The present invention relates to novel pyrimidine compounds, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer and inflammatory disease. The novel pyrimidine compounds according to the present invention remarkably inhibits activity of DRAK that inhibits signal systems of TGF-β, which is known to suppress cancer growth, and thus the novel pyrimidine compounds can be used as a pharmaceutical composition for preventing or treating cancer and can be used as a pharmaceutical composition for preventing or treating inflammatory disease.

公开(公告)号：US20150141439A1

公开(公告)日：2015-05-21

申请号：US14594448

申请日：2015-01-12

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

Inventor： Heeyeong CHO ,  Gildon CHOI ,  Woo Kyu PARK ,  Dae Young JEONG ,  Hyeon Young KIM ,  Sunkyung LEE ,  Do Hyun NAM ,  Ho Jun SEOL

IPC: A61K31/52 ,  A61K31/495

CPC classification number: A61K31/52 ,  A61K31/495

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer or Temodal resistant glioblastoma multiform comprising azathioprine as an active ingredient. The azathioprine of the present invention is not only effective in inhibiting the growth of glioblastoma multiform, a kind of brain tumor, but also excellent in treating glioblastoma multiform that displays resistance against Temodal (temozolomide), the conventional therapeutic agent for glioblastoma multiform, so that it can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of such cancer as brain tumor (particularly, glioblastoma multiform) and particularly Temodal resistant glioblastoma multiform.

Abstract translation: 本发明涉及用于预防或治疗包含硫唑嘌呤作为活性成分的多形态的癌症或耐炎性胶质母细胞瘤的药物组合物。 本发明的硫唑嘌呤不仅能有效抑制多形性成胶质细胞瘤的形成，而且是一种脑肿瘤，也是治疗多形性胶质母细胞瘤的优良表现，对于多形性胶质母细胞瘤的常规治疗药物Temodal（替莫唑胺）具有抗性， 它可以有效地用作药物组合物的活性成分，用于预防或治疗诸如脑肿瘤（特别是多形性胶质母细胞瘤）的癌症，特别是多形性的耐纹形胶质母细胞瘤。

公开(公告)号：US20240352000A1

公开(公告)日：2024-10-24

申请号：US18579279

申请日：2022-07-11

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Kwangho LEE ,  Krishna Babu DUGGIRALA ,  Gildon CHOI ,  Yujin LEE ,  Chong Hak CHAE ,  Myoung Eun JUNG ,  Byoung Chul CHO

IPC: C07D401/14 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00 ,  C07D403/12

CPC classification number: C07D401/14 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00 ,  C07D403/12

Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. The pyrimidine-2,4-diamine derivative exhibits a high inhibitory ability against EGFR and HER2 mutations, and thus can be advantageously used in the treatment of cancer in which EGFR and HER2 mutations have occurred. In addition, the pyrimidine-2,4-diamine derivative exhibits a significant synergistic effect when administered in combination, and thus may be advantageously used in combination therapy.